Table 6.

Risk-stratified schedule for NMIBC followup

Risk stratification	Surveillance schedule
Low-risk NMIBC	– Assessment with cystoscopy at 3 months – Cystoscopy at 1 year, then yearly until 5 years – Consider fulguration under local anesthesia for small (<5 mm), LG Ta tumors with negative cytology
Intermediate-risk NMIBC	– Assessment with cystoscopy and urine cytology at 3 months – Cystoscopy + urine cytology every 3–6 months for 2 years, every 6–12 months until 4th year and yearly thereafter
High-risk patients	– Assessment with cystoscopy and urine cytology at 3 months – Cystoscopy + urine cytology every 3–4 months for 2 years, every 6 months until 5th year and yearly thereafter – Upper tract evaluation within 12 months, then every 2 years thereafter

Modified and adapted from Kassouf et al.⁷⁸ LG: low-grade; NMIBC: non-muscle-invasive bladder cancer.